Efficacy and safety of hymenoptera venom immunotherapy.

IF 2.6 3区 医学 Q2 ALLERGY
Hazal Kayikci, Ozge Can Bostan, Gulseren Tuncay, Melek Cihanbeylerden, Ebru Damadoglu, Gul Karakaya, Ali Fuat Kalyoncu
{"title":"Efficacy and safety of hymenoptera venom immunotherapy.","authors":"Hazal Kayikci, Ozge Can Bostan, Gulseren Tuncay, Melek Cihanbeylerden, Ebru Damadoglu, Gul Karakaya, Ali Fuat Kalyoncu","doi":"10.2500/aap.2024.45.240035","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Being stung by Hymenoptera species can cause life-threatening anaphylaxis. Although venom immunotherapy (VIT) seems to be the most effective treatment, its long-term efficacy, and risk factors for adverse events remain unclear. <b>Objective:</b> The objective was to investigate the long-term efficacy of VIT and evaluate adverse events and risk factors related to this. <b>Method:</b> Patients who received VIT in a tertiary-care adult allergy clinic between January 2005 and July 2022 were included. Patients' data were compared with those of individuals who had been diagnosed with bee and/or wasp venom allergy during the same period but had not received VIT and experienced field re-stings. <b>Results:</b> The study included 105 patients with venom allergy, of whom 68 received VIT and 37 did not receive VIT. Twenty-three patients (34%) completed 5 years of VIT, and the overall mean ± standard deviation VIT duration was 46.9 ± 20.9 months. Re-stings occurred in 5 of 23 patients who completed 5 years of VIT, and none of them developed a systemic reaction. Eighteen patients (40%) experienced re-stings after prematurely discontinuing VIT, of whom eight (44%) developed a systemic reaction. In the control group of patients who did not receive VIT, 26 patients (70.3%) experienced re-stings, and all had systemic reactions (100%), with no change in their median Mueller scores. There was a significant difference in the median Mueller score change between the patients who received VIT and the controls who did not (p = 0.016). A total of 13 patients (19%) experienced adverse events while receiving VIT, which were systemic reactions in nine honeybee VIT. The use of β-blockers was determined as the most important risk factor (odds ratio 15.9 [95% confidence interval, 1.2-208.8]; p = 0.035). <b>Conclusion:</b> It was confirmed that VIT was effective in both reducing the incidence and the severity of re-sting reactions. These effects were more pronounced in the patients who completed 5 years of VIT.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 4","pages":"268-275"},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy and asthma proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2500/aap.2024.45.240035","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Being stung by Hymenoptera species can cause life-threatening anaphylaxis. Although venom immunotherapy (VIT) seems to be the most effective treatment, its long-term efficacy, and risk factors for adverse events remain unclear. Objective: The objective was to investigate the long-term efficacy of VIT and evaluate adverse events and risk factors related to this. Method: Patients who received VIT in a tertiary-care adult allergy clinic between January 2005 and July 2022 were included. Patients' data were compared with those of individuals who had been diagnosed with bee and/or wasp venom allergy during the same period but had not received VIT and experienced field re-stings. Results: The study included 105 patients with venom allergy, of whom 68 received VIT and 37 did not receive VIT. Twenty-three patients (34%) completed 5 years of VIT, and the overall mean ± standard deviation VIT duration was 46.9 ± 20.9 months. Re-stings occurred in 5 of 23 patients who completed 5 years of VIT, and none of them developed a systemic reaction. Eighteen patients (40%) experienced re-stings after prematurely discontinuing VIT, of whom eight (44%) developed a systemic reaction. In the control group of patients who did not receive VIT, 26 patients (70.3%) experienced re-stings, and all had systemic reactions (100%), with no change in their median Mueller scores. There was a significant difference in the median Mueller score change between the patients who received VIT and the controls who did not (p = 0.016). A total of 13 patients (19%) experienced adverse events while receiving VIT, which were systemic reactions in nine honeybee VIT. The use of β-blockers was determined as the most important risk factor (odds ratio 15.9 [95% confidence interval, 1.2-208.8]; p = 0.035). Conclusion: It was confirmed that VIT was effective in both reducing the incidence and the severity of re-sting reactions. These effects were more pronounced in the patients who completed 5 years of VIT.

膜翅目昆虫毒液免疫疗法的有效性和安全性。
背景:被膜翅目昆虫蛰伤会导致过敏性休克,危及生命。尽管毒液免疫疗法(VIT)似乎是最有效的治疗方法,但其长期疗效和不良反应的风险因素仍不清楚。研究目的目的:调查毒液免疫疗法的长期疗效,并评估与此相关的不良事件和风险因素。方法:纳入 2005 年 1 月至 2022 年 7 月期间在一家三级医疗机构成人过敏诊所接受 VIT 治疗的患者。将患者的数据与同期被诊断为对蜜蜂和/或黄蜂毒液过敏但未接受过 VIT 并经历过现场再刺的患者的数据进行比较。研究结果研究包括 105 名毒液过敏患者,其中 68 人接受了 VIT,37 人未接受 VIT。23 名患者(34%)完成了为期 5 年的 VIT,总体平均 VIT 持续时间为 46.9±20.9 个月。在 23 名完成 5 年 VIT 的患者中,有 5 名患者出现了再次注射的情况,但没有一人出现全身反应。18 名患者(40%)在过早停用 VIT 后再次发生感染,其中 8 人(44%)出现全身反应。在未接受 VIT 的对照组患者中,有 26 名患者(70.3%)再次发生荨麻疹,全部出现全身反应(100%),穆勒评分中位数没有变化。接受 VIT 的患者与未接受 VIT 的对照组在中位 Mueller 评分变化上存在明显差异(p = 0.016)。共有 13 名患者(19%)在接受 VIT 治疗期间出现了不良反应,其中 9 名蜜蜂 VIT 患者出现了全身反应。使用β-受体阻滞剂被认为是最重要的风险因素(几率比15.9[95%置信区间,1.2-208.8];p = 0.035)。结论研究证实,VIT 能有效降低再次刺痛反应的发生率和严重程度。这些效果在完成 5 年 VIT 治疗的患者中更为明显。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
35.70%
发文量
106
审稿时长
6-12 weeks
期刊介绍: Allergy & Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists. The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma. Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信